Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Evaluating Results???... Wonder Whats Really Going On
HDC 10K Filed 3/31/11:
We continue to progress towards the goal of commercialization of the 4-gene urine-based prostate cancer test at Quest and with Abbott Upon completion of development and validation to the satisfaction of Quest, the 4-gene urine test for prostate cancer can be immediately commercialized as an LDT under the current CLIA regulations. Upon regulatory approval, Abbott could immediately begin commercialization and sale of the individual In-VitroDiagnostic (IVD) test kits to additional national, regional and local clinical laboratories, as well as hospital, academic and physician laboratories around the world.
HDC 10Q Filed 5/16/11:
Please refer to our Annual Report on Form 10-K filed on March 31, 2011 for further information regarding updates with our business.
HDC 10Q Filed 8/15/11:
We continue to progress towards the goal of commercialization of the 4-gene urine-based prostate cancer test at Quest and with Abbott. The clinical trials for both Abbott and Quest studies have been completed and the Company is currently in the process of evaluating the results with Abbott and Quest.
EZ$,
If you have patience, we could get an update in the very near future. The 10Q is due on Monday, 8/15/11.
“This widespread adoption of the technology translates directly to licensing opportunities through the Company’s university licensing program along with a soon-to-be-announced program for patent enforcement against commercial users,” said Dr. Barnhill.
It was ok while it lasted giving some reason to hope. StormKing must have moved on. Now we wait for Droid and other app releases but what about everything else? Interesting to see if anything is released before the 10Q due in mid August.
Thanks Stone$. Disappointed that none of the analysts followed-up on it from the previous CC. DGX continues to drift lower on the lack-luster presentation. We can only hope that the test is still alive with both Abbott & Quest.
Will Any Of The Analysts Ask The 4 Gene Question????
http://ir.questdiagnostics.com/phoenix.zhtml?c=82068&p=irol-newsArticle&ID=1582710&highlight=
Thank you Storm! Appreciate the update and comments. I don't mean to be a pest but if you get a chance could you take a look at Skin Scan and post your comparative assessment. Many thanks again.
Has Quest decided to take another route???????
Quest and Genomic Vision Tie Up:
"Quest has made an equity investment in Genomic Vision for an undisclosed amount. The company believes that DNA combing can help in clinical testing and drug development based on its ability to analyze single DNA molecules."
http://finance.yahoo.com/news/Quest-Diagnostics-and-Genomic-prnews-2272807807.html?x=0&.v=1
Concerns About Skin Scan (Our Competition)
In case you haven't seen this:
"Bowling tested five cancerous moles, the app ruled three of them either medium risk, or low risk."
http://www.3news.co.nz/Concern-surrounds...
Please Post Your MelApp Comments on Facebook & Twitter
http://www.facebook.com/MelApp
http://twitter.com/#!/SafeHealthApps
Thanks Storm. HDC owns 100% of this technology and I agree there could be a significant revenue source if can get traction with multiple releases and the physician referral system.
Thanks Storm. Especially appreciate your comments.
MelApp Droid Version Out Soon .....
When I asked Brenda Becker at Trevelino/Keller the question; Is there a way to send a digital picture in for a SVM assessment?... The response was:
"Unfortunately, no. The tech currently only works as a service for iPhone iPod Touch and iPad, with a Droid version soon to follow."
Storm,
After months of silence by the company, we are finally seeing signs that we may have arrived at the "very near future". Not only that,.... we may also (hopefully) have a resident app expert (you) who knows how to get and interpret the performance data for HDC's first commercial technology launch!! I hope you decide to stick around for awhile to see if HDC is in fact "at the tipping point of a series of noteworthy product launches". If time permits, please continue to advise on the MelApp ranking trends. Thank you and best of luck to you with MRNJ and to all with HDVY.
Many thanks Storm. Will be interesting to see how our MelApp ranks in the coming weeks. Don't recall ever owning shares in a company where you could track the sales performance of a product like this. Understand it could go both ways but hoping for the best.
SK,
Could you please post a Skin Scan IPhone Rank Grosing for comparison? TIA.
HDC will need to differentiate the MelApp technology from Skin Scan which is available at the iTunes Apple Store for a promotional price of $4.99.
http://news.yahoo.com/iphone-app-may-det...
HDC will also need to check for infringement.
Please post a link. Thanks.
Guess you could say many of us are "still waiting for our ship to come in".
“Well, first of all, as we said, that any acquisition for us has to fit in strategically and has to make economic sense. And now you folks can realize why we waited to do the things that was really in line with our strategy to get into new platforms. Athena was a new platform for neurological disorders. Celera is a new platform for cardiovascular disease, but more importantly in discovery and development. And we will continue to invest money in these type of acquisitions as we go forward.”
Surya Mohapatra, - DGX Chairman, Chief Executive Officer, President and Chairman of Executive Committee
Selling that has taken out that huge bid at $0.13 today. Let's see where we will be at the close.
StoneMo,
That's right! You nailed it!!! Got to be getting close to that TG JV... He couldn't have rec'd 2.5 MILLION warrants for,.... for,...nothing........ I mean Holey Sheet.. All those other potential applications in so many different fields of operation. TWO MILLION FIVE HUNDRED THOUSAND for nothing??? Can't be the end of the TG story...... No wonder the shares busted through to a recent high of 15 cents. I'm calling the company tomorrow. They never got back to me about whether or not Tom returned their voice-mail messages.
Been around too long and my concerns continue also. No launch yet with Quest bothers me the most but I try to discount it with:
(1)Dr. B taking a 100K bonus…. Must mean something extraordinary has happened
(2)Officers& Directors awarded huge option grants….. Must have done something for the shareholders or an acquisition is just around the corner
(3)Recent SEC filings portend higher share prices….. How could they exercise and liquidate their positions if there isn’t massive public demand for the shares?
(4)Start of the IP Enforcement Policy this Q….. Can’t wait to here about the progress
(5)I-Phone Melanoma App……Wasn’t it supposed to launch last year or is it this year?
(6)SVM Capital…… Waiting for this investment choice to appear in my Fidelity 401K
(7)Strategic Alliance with Adaptive……Wasn’t that supposed to bear fruit last year or ..?
(8) Waiting for prior art affirmation and withdrawal of the Intel RFE-SVM patent.
(9) Listened to the Quest CC and heard the GS analyst (Shelley) ask about the 4 Gene test.
(10) Heard Kathleen Valentine (DIR, DGX) say:
“Oh, the 4-gene. Okay, yes. It's still in development, Shelley. And while it's in development, we don't have anything to comment on yet. But we're pleased with the progress that it's making. And then when we get to a stage where we have something to disclose, we certainly will do so.”
(11) Deal with Smart Personalized Medicine & Quest
(12) Waiting for partnerships for the new pancreatic cancer tests
(13) Waiting for a partner to commercialize a new molecular diagnostic test for BPH
(14) Waiting for partners to use HDC’s patent-protected colon cancer-specific biomarkers to develop tests for colon cancer and even a potential vaccine.
(15)Waiting for HDC’s “Lead Director” to prepare the documents and assemble the BOD for another vote to award Dr. B with another $100K bonus in order to secure shareholder belief that the glass is half full
(16)Repeating my personal Mantra “VRY NERE FUTUR” over and over again
OVA1..Best Thing Since Sliced Bread...Again
"In this study, OVA1 identified 98% of early stage epithelial ovarian cancers compared to 68% identified by CA 125. Furthermore, OVA1 identified 93% of premenopausal early stage cancers compared to only 36% identified by CA 125."
http://ir.questdiagnostics.com/phoenix.zhtml?c=82068&p=irol-newsArticle&ID=1567179&highlight=
Jayree,
William F. Quirk, Jr. and Prime Mover Capital Partners , L.P. are listed as the "Selling Shareholders" in the recent AMENDMENT No. 1 to FORM S-1 REGISTRATION STATEMENT filing.
Where do you see that Barnhill is selling almost a million shares? Can you please post a link? Thanks.
Quest Diagnostics Successfully Completes Acquisition of Celera
http://ir.questdiagnostics.com/phoenix.zhtml?c=82068&p=irol-newsArticle&ID=1564836&highlight=
Wonder whats next on the list of things to do?
From Prospectus Supplement No. 1 dated May 18, 2011:
"Our Annual Report on Form 10-K contains information regarding a material weakness in our internal control over financial reporting as of December 31, 2010 due to an inadequate segregation of duties due to the small number of employees. The Company anticipates that this material weakness will be satisfactorily addressed in the near future."
Notice the last sentence above. Although it doesn't say "in the very near future", it expresses a change in expected resolution as compared to the same statement in the 10K.
Wonder why the expectation of change and how many more prospectus supplements are coming????
Drink Lots of Coffee While Waiting for the Pee Test
http://www.npr.org/blogs/health/2011/05/18/136402267/coffee-lowers-risk-of-deadliest-prostate-cancer?ft=1&f=100
10Q Summary:
"Please refer to our Annual Report on Form 10-K filed on March 31, 2011 for further information regarding updates with our business"
Please let me know if I missed something. Thanks.
ZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ ZZZZZZZZZZZZ
OVA1 Blood Test Detects Ovarian Cancer More Accurately Than Medically Accepted CA 125
http://ir.questdiagnostics.com/phoenix.zhtml?c=82068&p=irol-newsArticle&ID=1563258&highlight=
Important Comments from the Chairman of DGX:
Surya Mohapatra - Chairman, Chief Executive Officer, President and Chairman of Executive Committee
Surya Mohapatra
Well, we have been anticipating changes in healthcare reform, and how our company is going to grow both top line and bottom line in the coming years. So over the last four or five years, we've stated our strategies that we're going to invest money in esoteric, gene-based testing and anatomic pathology, and that's what we have done over the last three or four years. And then last year or 18 months ago, we stated also that we're going to build up specialty sales force because we think our future is in science and innovation. Our future is beginning in proprietary products to solve the unmet needs of the four disease area, which is the growth areas: cancer, infectious disease and cardiovascular disease and neurological disorders. So what you are really seeing is, to some extent, how we are transforming our company just from a lab company to a diagnostics company, now we're getting into the science and innovation. And we believe for our shareholders and for our patients, this is the best strategy, and we are just executing our strategy, what we said three or four years ago.
Surya Mohapatra
Well, first of all, as we said, that any acquisition for us has to fit in strategically and has to make economic sense. And now you folks can realize why we waited to do the things that was really in line with our strategy to get into new platforms. Athena was a new platform for neurological disorders. Celera is a new platform for cardiovascular disease, but more importantly in discovery and development. And we will continue to invest money in these type of acquisitions as we go forward. Now, as regards to other fold-in acquisitions, that is a routine task for us and if it is available at appropriate value, we'll always look into fold-in acquisitions for lab. But our focus remains to build up Quest Diagnostics as the most innovative company by investing in science and innovation.
Surya Mohapatra
Well, first of all, the M&A strategy, in the stated strategy. We told three or four years ago that we're going to diversify more and more towards esoteric and gene-based and anatomic pathology, and that's what we have been doing. And as you know, 36% of our total revenue now is in this high-margin and high-growth areas. Now, of course, there are some market dynamics with the changes, like in anatomic pathology, we are going through a tough time in physician insourcing. Of course, we are working with a trade association for legislative changes in that. So the way we look at it is, to some extent, Quest Diagnostics is going towards creating a new Quest Diagnostics where we are really looking at the four disease areas. And these platforms are the reason why we could say we can serve the cancer patients effectively, cardiac patients effectively , neurological patients effectively, and infectious disease. Now that gives us the competitive advantage compared to other companies in the United States and our competitors. So although it is not reflected in this year and we don't give long-term guidance, but we are very, very excited about the long-term future of the company and our role as the industry leader, what we can do for our patients and what we can do for our shareholders
From The DGX Conference Call Transcript:
(Shelly Gnall is from Goldman Sachs)
Shelley Gnall-Sazenski
Understood. And then just a quick one. I understand you've got a 4-gene urinalysis prostate cancer test under development. Can you give us any update on this test, where it is and whether it's expected to be an important test?
Kathleen Valentine
You threw me off with the name. 4G?
Shelley Gnall-Sazenski
The 4-gene.
Kathleen Valentine
Oh, the 4-gene. Okay, yes. It's still in development, Shelley. And while it's in development, we don't have anything to comment on yet. But we're pleased with the progress that it's making. And then when we get to a stage where we have something to disclose, we certainly will do so.
Shelley Gnall-Sazenski
Okay, great. Thanks, very much.
Goldman Sachs Analyst Asked The PC Test Question on the CC!!!
When she asked about the "4 gene" test the response was something like "we are pleased with the results and will make an announcement at an appropriate time" To listen to the CC replay:
866-350-3614
News! Biomed Report Update
http://biomedreports.com/2011041966049/health-discovery-corporation-update.html
Quirk's 2 year Warrant Exercise Window:
On September 22, 2010, Mr. Quirk exchanged his 32,527,776 warrants for 10,000,000 new warrants. The 10,000,000 new warrants consist of three tranches; two of which are for 3,333,333 warrants each and one for 3,333,334 warrants, with strike prices of $0.20, $0.25 and $0.30 (subject to certain exercise price adjustments), and exercise terms of 12 months,18 months and 24 months, respectively.
With the people moves, grants and filings we are now seeing, it certainly appears to be posturing for something (hopefully positive) in the very near future.
Its a great deal for Quirk and I am aware that he will be able to exercise the warrants and receive shares with a price adjustment but isn't it necessary that the stock trade for a specified period of time at the 0.20, 0.25 & 0.30 prices levels before he can convert?
Higher Stock Price Needed For This
http://www.sec.gov/Archives/edgar/data/1141788/000118811211001066/t70396_s1a.htm